F S&P 500
4,593.25 -7.50 (-0.16%) F Dow Jones
36,283.00 -20.00 (-0.06%) F Nasdaq
15,974.00 -49.75 (-0.31%) Russell 2000 Futures
1,864.30 -1.40 (-0.08%) Petróleo
73.46 -0.61 (-0.82%) Oro
2,103.20 +13.50 (+0.65%)
Biohaven Ltd. (BHVN)
Fuera de horario:
Biohaven Ltd.
215 Church Street
New Haven, CT 06510
United States
203 404 0410
https://www.biohaven.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Vladimir Coric M.D. | Chairman & CEO | 1.85M | N/D | 1971 |
| Mr. Matthew Buten | Chief Financial Officer | 939.45k | N/D | 1961 |
| Dr. Bruce D. Car DACVP, Ph.D. | Chief Scientific Officer | 646.89k | N/D | 1962 |
| Ms. Deb Young | Director of Regulatory Affairs & Operations | N/D | N/D | N/D |
| Mr. George C. Clark | VP & Chief Accounting Officer | N/D | N/D | 1984 |
| Ms. Jennifer Porcelli | Vice President of Investor Relations | N/D | N/D | N/D |
| Mr. Warren Volles J.D. | General Counsel & Chief Legal Officer | N/D | N/D | N/D |
| Mr. Clifford Bechtold M.S. | Chief Compliance Officer | N/D | N/D | N/D |
| Ms. Kimberly Gentile | Senior Vice President of Clinical Operations | N/D | N/D | 1966 |
| Mr. John Tilton | Chief Commercial Officer of Rare Diseases | N/D | N/D | 1968 |
Descripción
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
Gestión corporativa
La calificación ISS Governance QuickScore de Biohaven Ltd. a partir del 1 de diciembre de 2023 es 5. Las puntuaciones principales son Auditoría: 4; Junta: 6; Derechos del accionista: 3; Compensación: 8.
